Results 81 to 90 of about 103,961 (275)

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

Urology Case Reports, 2020
In the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related
Shinro Hata, Satoki Abe
doaj   +1 more source

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

American Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen, Joachim Baech, Mikkel Porsborg Andersen, Harman Yonis, Paw Jensen, Peter Kamper, Jacob H. Christensen, Rasmus Bo‐Dahl Sørensen, Martin Hutchings, Christian Torp‐Pedersen, Peter Sogaard, Henrik Boggild, Kristian H. Kragholm, Tarec C. El‐Galaly   +13 more
wiley   +1 more source

Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome [PDF]

, 2018
Stevens-Johnson syndrome is a rare adverse cutaneous drug reaction characterized by epidermal detachment of
Al-Omari, Ahmed, Rancour, Elizabeth A., Shah, Kishan M.   +2 more
core  

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Cancer Medicine
Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in ...
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani   +21 more
doaj   +1 more source

Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

Haematologica
Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as Nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL).
Kübra Yadigaroglu, Sonja Scharf, Steffen Gretser, Hendrik Schäfer, Aresu Sadeghi Shoreh Deli, Andreas G. Loth, Hasmik Yegoryan, Roland Schmitz, Emmanuel Donnadieu, Martin-Leo Hansmann, Sylvia Hartmann   +10 more
doaj   +1 more source

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. [PDF]

, 2016
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Oronsky, Bryan, Reid, Tony R, Scicinski, Jan   +7 more
core   +3 more sources

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab

Respiratory Medicine Case Reports, 2020
A 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was ...
Keima Ito, Tetsuya Oguri, Norihisa Takeda, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi   +11 more
doaj   +1 more source

Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases [PDF]

, 2018
Purpose: We performed a phase I study to determine the maximum tolerable dose (MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Andrews MD, David W., Daskalakis, Constantine, Dicker, Adam, MD, PhD, Eldredge-Hindy, Harriet B., Evans, James J., Farrell, MD, Christopher J, Feeney, Kendra J., Garg, Shivank, Judy, MD, Kevin, Kendra, Kari L., Kim, Lyndon, Kim, MD, Hyun, Liebner, David A., Mastrangelo, Michael, Olencki, Thomas, Palmer, Joshua D., Sato, Takami, Shi, Wenyin, Werner-Wasik, Maria, Williams, Noelle L., Wuthrick, Evan J.   +20 more
core   +2 more sources